MERSANA THERAPEUTICS INC's ticker is MRSN and the CUSIP is 59045L106. A total of 158 filers reported holding MERSANA THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 0.09 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $723 | +460.5% | 219,846 | +601.4% | 0.03% | +416.7% |
| Q1 2023 | $129 | -62.5% | 31,346 | -46.6% | 0.01% | -68.4% |
| Q4 2022 | $344 | -99.9% | 58,658 | 0.0% | 0.02% | -20.8% |
| Q3 2022 | $397,000 | +154.5% | 58,658 | +133.7% | 0.02% | +26.3% |
| Q4 2021 | $156,000 | -7.7% | 25,102 | +40.3% | 0.02% | -13.6% |
| Q3 2021 | $169,000 | -31.9% | 17,892 | +92.1% | 0.02% | -69.0% |
| Q4 2020 | $248,000 | -68.9% | 9,312 | -72.7% | 0.07% | -73.8% |
| Q2 2020 | $797,000 | +226.6% | 34,061 | -18.7% | 0.27% | +163.1% |
| Q1 2020 | $244,000 | -18.1% | 41,881 | -19.5% | 0.10% | +15.7% |
| Q4 2019 | $298,000 | +388.5% | 52,031 | +34.3% | 0.09% | +287.0% |
| Q3 2019 | $61,000 | -61.1% | 38,731 | 0.0% | 0.02% | -60.3% |
| Q2 2019 | $157,000 | +42.7% | 38,731 | +85.0% | 0.06% | -7.9% |
| Q1 2019 | $110,000 | – | 20,933 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 1,191,271 | $6,980,848 | 6.79% |
| Bain Capital Life Sciences Investors, LLC | 8,663,673 | $50,769 | 5.67% |
| ACUTA CAPITAL PARTNERS, LLC | 950,000 | $5,567,000 | 3.43% |
| Sarissa Capital Management LP | 3,997,010 | $23,422,479 | 2.79% |
| Decheng Capital Management III (Cayman), LLC | 904,268 | $5,299,010 | 1.98% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 1,140,182 | $6,681,467 | 1.91% |
| Orbimed Advisors | 9,011,437 | $52,807,021 | 1.01% |
| Opaleye Management Inc. | 460,000 | $2,695,600 | 0.94% |
| Artal Group S.A. | 2,200,000 | $12,892 | 0.72% |
| DAFNA Capital Management LLC | 413,463 | $2,422,893 | 0.68% |